United States Ivosidenib Drugs Market was valued at USD 0.15 Billion in 2022 and is projected to reach USD 0.60 Billion by 2030, growing at a CAGR of 18.5% from 2024 to 2030.
Start
The U.S. Ivosidenib Drugs Market Has Experienced Notable Growth, Primarily Due To Its Efficacy In Treating Specific Cancers. Ivosidenib, Marketed Under The Brand Name Tibsovo, Is An Isocitrate Dehydrogenase-1 (Idh1) Inhibitor Approved By The Fda For Treating Acute Myeloid Leukemia (Aml) And Cholangiocarcinoma With Idh1 Mutations. CiteTurn0Search2
Market Overview
In 2024, The Global Ivosidenib Market Was Valued At Approximately $18.5 Million, With North America Accounting For Over 40% Of The Revenue, Equating To Around $7.40 Million. The Market Is Projected To Grow At A Compound Annual Growth Rate (Cagr) Of 2.4% From 2024 To 2031. CiteTurn0Search6
Industry Requirements
Regulatory Approvals: Pharmaceutical Companies Must Secure Fda Approval, Demonstrating The Drug'S Safety And Efficacy. CiteTurn0Search3
Manufacturing Standards: Compliance With Good Manufacturing Practices (Gmp) Ensures Product Quality And Safety.
Clinical Trials: Conducting Rigorous Clinical Trials Is Essential To Validate The Drug'S Effectiveness And Monitor Adverse Reactions. CiteTurn0Search3
Diagnostic Testing: Accurate Diagnostic Tests Are Crucial To Identify Patients With Idh1 Mutations Who Would Benefit From Ivosidenib Treatment.
Healthcare Professional Training: Educating Healthcare Providers On Patient Selection, Dosing, And Managing Potential Side Effects Is Vital For Optimal Treatment Outcomes.
Challenges And Considerations
Despite Its Benefits, Ivosidenib Treatment Can Lead To Adverse Reactions Such As Gastrointestinal Issues, Fatigue, And Qtc Prolongation. The Fda Has Issued A Boxed Warning Regarding The Risk Of Differentiation Syndrome, Which Can Be Life-Threatening Or Fatal. CiteTurn0Search3
Additionally, Disparities In Diagnostic Testing Can Affect Treatment Accessibility. For Instance, In Scotland, Patients Have Had To Pay For Dna Testing To Access Ivosidenib, Whereas Such Tests Are Provided Free In England. CiteTurn0News13
Conclusion
The U.S. Ivosidenib Drugs Market Continues To Grow, Driven By Its Targeted Approach To Treating Cancers With Idh1 Mutations. However, Addressing Challenges Such As Side Effect Management And Ensuring Equitable Access To Diagnostic Testing Are Crucial For Maximizing Its Therapeutic Potential.
Get an In-Depth Research Analysis of the US Ivosidenib Drugs Market Size And Forecast [2025-2032]
Agios Pharmaceuticals
Agios Pharmaceuticals
By the year 2030, the scale for growth in the market research industry is reported to be above 120 billion which further indicates its projected compound annual growth rate (CAGR), of more than 5.8% from 2023 to 2030. There have also been disruptions in the industry due to advancements in machine learning, artificial intelligence and data analytics There is predictive analysis and real time information about consumers which such technologies provide to the companies enabling them to make better and precise decisions. The Asia-Pacific region is expected to be a key driver of growth, accounting for more than 35% of total revenue growth. In addition, new innovative techniques such as mobile surveys, social listening, and online panels, which emphasize speed, precision, and customization, are also transforming this particular sector.
Get Discount On The Purchase of the US Ivosidenib Drugs Market Size And Forecast [2025-2032]
Growing demand for below applications around the world has had a direct impact on the growth of the US Ivosidenib Drugs Market
Oral Tablets
Injectable Formulations
Combination Therapies
Extended-Release Tablets
Acute Myeloid Leukemia (AML)
Cholangiocarcinoma
Solid Tumors
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Specialty Pharmacies
Hospitals
Oncology Clinics
Research Institutions
Home Healthcare
Pediatrics
Adults
Elderly
Gender-specific s
US (United States, US and Mexico)
Europe (Germany, UK, France, Italy, Russia, Turkey, etc.)
Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)
South America (Brazil, Argentina, Columbia, etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
For More Information or Query, Visit @ Ivosidenib Drugs Market Research Analysis
1. Introduction of the US Ivosidenib Drugs Market
Overview of the Market
Scope of Report
Assumptions
2. Executive Summary
3. Research Methodology of Verified Market Reports
Data Mining
Validation
Primary Interviews
List of Data Sources
4. US Ivosidenib Drugs Market Outlook
Overview
Market Dynamics
Drivers
Restraints
Opportunities
Porters Five Force Model
Value Chain Analysis
5. US Ivosidenib Drugs Market, By Type
6. US Ivosidenib Drugs Market, By Application
7. US Ivosidenib Drugs Market, By Geography
US
Europe
Asia Pacific
Rest of the World
8. US Ivosidenib Drugs Market Competitive Landscape
Overview
Company Market Ranking
Key Development Strategies
9. Company Profiles
10. Appendix
About Us: Verified Market Reports
Verified Market Reports is a leading US Research and Consulting firm servicing over 5000+ US clients. We provide advanced analytical research solutions while offering information-enriched research studies. We also offer insights into strategic and growth analyses and data necessary to achieve corporate goals and critical revenue decisions.
Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance using industrial techniques to collect and analyze data on more than 25,000 high-impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.
Contact us:
Mr. Edwyne Fernandes
US: +1 (650)-781-4080
US Toll-Free: +1 (800)-782-1768
Website: https://www.verifiedmarketreports.com/